Journal
NATURE MEDICINE
Volume 24, Issue 7, Pages 1036-+Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41591-018-0052-4
Keywords
-
Funding
- Center for Co-Clinical Trials, Institute for Applied Cancer Science
- Glioblastoma (GBM)
- AML/MDS Moon Shots
- Agilent Technologies Thought Leader Award
- Medical Research Council [MC U105663141, MC UU 00015/2]
- CPRIT grant [RP140218, RP140612]
- National Institutes of Health (NIH) Brain SPORE [P50CA127001]
- American Association for Cancer Research (AACR) [14-90-25]
- Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Grant
- Leukemia & Lymphoma Society through its Therapy Acceleration Program (TAP)
- MD Anderson Moon Shots program
- [RSG1514501CDD]
- MRC [MC_U105663141, MC_UU_00015/2] Funding Source: UKRI
Ask authors/readers for more resources
Metabolic reprograming is an emerging hallmark of tumor biology and an actively pursued opportunity in discovery of oncology drugs. Extensive efforts have focused on therapeutic targeting of glycolysis, whereas drugging mitochondrial oxidative phosphorylation (OXPHOS) has remained largely unexplored, partly owing to an incomplete understanding of tumor contexts in which OXPHOS is essential. Here, we report the discovery of IACS-010759, a clinical-grade small-molecule inhibitor of complex I of the mitochondrial electron transport chain. Treatment with IACS-010759 robustly inhibited proliferation and induced apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS, likely owing to a combination of energy depletion and reduced aspartate production that leads to impaired nucleotide biosynthesis. In models of brain cancer and AML, tumor growth was potently inhibited in vivo following IACS-010759 treatment at well-tolerated doses. IACS-010759 is currently being evaluated in phase 1 clinical trials in relapsed/refractory AML and solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available